Filtered By:
Specialty: Hematology
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 2753 results found since Jan 2013.
CircSEC11A knockdown alleviates oxidative stress and apoptosis and promotes cell proliferation and angiogenesis by regulating miR-29a-3p/SEMA3A axis in OGD-induced human brain microvascular endothelial cells (HBMECs)
CONCLUSION: CircSEC11A promoted the malignant progression in OGD-induced HBMECs through the mediation of miR-29a-3p/SEMA3A axis. This study has provided the new insight into the underlying application of circSEC11A in cell model of ischemic stroke.PMID:36872771 | DOI:10.3233/CH-221689
Source: Clinical Hemorheology and Microcirculation - March 6, 2023 Category: Hematology Authors: Ziying Zhou Qian Hu Hongmei Guo Xijia Wang Source Type: research
Consistency of left ventricular ejection fraction measurements in the early time course of STEMI
CONCLUSIONS: 2D analysis of LVEF yielded robust results across all imaging techniques implying that CVG, 2DE, and 2D CMR can be used interchangeably early after STEMI. SV measurements differed substantially between imaging techniques due to higher intermodality-differences of absolute volumetric measurements.PMID:36872773 | DOI:10.3233/CH-231734
Source: Clinical Hemorheology and Microcirculation - March 6, 2023 Category: Hematology Authors: Lilyana Georgieva Fabian T Nienhaus Sebastian Haberkorn Ralf Erkens Amin Polzin Patricia Wischmann Rojda Ipek Kian Marjani Aikaterini Christidi Michael Roden Christian Jung Florian B önner Malte Kelm Stefan Perings Mareike Gastl Source Type: research
CircSEC11A knockdown alleviates oxidative stress and apoptosis and promotes cell proliferation and angiogenesis by regulating miR-29a-3p/SEMA3A axis in OGD-induced human brain microvascular endothelial cells (HBMECs)
CONCLUSION: CircSEC11A promoted the malignant progression in OGD-induced HBMECs through the mediation of miR-29a-3p/SEMA3A axis. This study has provided the new insight into the underlying application of circSEC11A in cell model of ischemic stroke.PMID:36872771 | DOI:10.3233/CH-221689
Source: Clinical Hemorheology and Microcirculation - March 6, 2023 Category: Hematology Authors: Ziying Zhou Qian Hu Hongmei Guo Xijia Wang Source Type: research
DOACs plasma levels in relation to clinical outcome. How far have we come?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research
DOACs plasma levels in relation to clinical outcome. How far have wecome?
Direct oral anticoagulants (DOACs) are the preferred treatment for prevention of ischemic stroke (IS) and systemic embolism (SE) in nonvalvular atrial fibrillation (NVAF) and treatment or prevention of venous thromboembolism (VTE) [1]. DOACs are administered in fixed doses and do not require routine laboratory monitoring [2]. Nonetheless, high interindividual variability of DOAC blood levels has been reported and the correlation between DOAC plasma levels and clinical outcome is still a grey area.
Source: Thrombosis Research - March 3, 2023 Category: Hematology Authors: Rosa Talerico, Roberto Pola, Menno Volkert Huisman, Frederikus Albertus Klok Tags: Letter to the Editors-in-Chief Source Type: research
Protocol for a Systematic Review and Individual Participant Data Meta-Analysis of Randomized Trials of Screening for Atrial Fibrillation to Prevent Stroke
Thromb Haemost. 2023 Mar;123(3):366-376. doi: 10.1055/s-0042-1760257. Epub 2023 Mar 2.ABSTRACTINTRODUCTION: Atrial fibrillation (AF) is a common cause of stroke. Timely diagnosis of AF and treatment with oral anticoagulation (OAC) can prevent up to two-thirds of AF-related strokes. Ambulatory electrocardiographic (ECG) monitoring can identify undiagnosed AF in at-risk individuals, but the impact of population-based ECG screening on stroke is uncertain, as ongoing and published randomized controlled trials (RCTs) have generally been underpowered for stroke.METHODS AND ANALYSIS: The AF-SCREEN Collaboration, with support from...
Source: Thrombosis and Haemostasis - March 2, 2023 Category: Hematology Authors: AF SCREEN and AFFECT-EU Collaborators Source Type: research
Spatiotemporal profile of neutrophil extracellular trap formation in a mouse model of ischemic stroke
CONCLUSION: This study identified the spatiotemporal profile of NET formation in a mouse model of cerebral I/R injury in ischemic stroke. NETs, potentially in combination with VWF, might be attractive targets for the development of novel therapeutic strategies in ischemic stroke treatment.PMID:36852112 | PMC:PMC9958086 | DOI:10.1016/j.rpth.2022.100028
Source: Thrombosis and Haemostasis - February 28, 2023 Category: Hematology Authors: Maaike De Wilde Linda Desender Claudia Tersteeg Karen Vanhoorelbeke Simon F De Meyer Source Type: research
Direct Oral Anticoagulants: Laboratory Challenges and Antidotes
In conclusion, although DOACs make long-term anticoagulation safer and more convenient for patients, DOACs pose challenge to all healthcare providers involved in anticoagulation decisions. The key to correct patient management and optimal outcome therefore lies in education.PMID:36807818 | DOI:10.1055/a-1987-3559
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Jan Beyer-Westendorf Christina K öhler Source Type: research
A Review of FXIa Inhibition as a Novel Target for Anticoagulation
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.ABSTRACTLimitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy but an overall better safety profile, lack of routine monitoring, and very limited drug-drug interactions compared with agents such as warfarin. However, an increased risk of bleeding remains even with these new-generation oral anticoagulants in fragile patient populations, in patients requiring dual or triple antithrombotic therapy, or high bleed...
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Ioannis Koulas Alex C Spyropoulos Source Type: research
Direct Oral Anticoagulants: Laboratory Challenges and Antidotes
In conclusion, although DOACs make long-term anticoagulation safer and more convenient for patients, DOACs pose challenge to all healthcare providers involved in anticoagulation decisions. The key to correct patient management and optimal outcome therefore lies in education.PMID:36807818 | DOI:10.1055/a-1987-3559
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Jan Beyer-Westendorf Christina K öhler Source Type: research
A Review of FXIa Inhibition as a Novel Target for Anticoagulation
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.ABSTRACTLimitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy but an overall better safety profile, lack of routine monitoring, and very limited drug-drug interactions compared with agents such as warfarin. However, an increased risk of bleeding remains even with these new-generation oral anticoagulants in fragile patient populations, in patients requiring dual or triple antithrombotic therapy, or high bleed...
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Ioannis Koulas Alex C Spyropoulos Source Type: research
